483
Dixon Investments IncFDA 483 - Dixon Investments Inc - March 22, 2019
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
Record Details
Dixon Investments, Inc. DBA ARI, an OTC liquid and aerosol drug manufacturer in Orchard Hill, GA, was inspected by the FDA. The inspection revealed significant deficiencies in manufacturing process validation, quality control testing, discrepancy investigations, and stability testing. Several observations were repeat findings, indicating persistent issues with GMP compliance.
- Office
- Atlanta District Office
- Person
Open in Dashboard
ID · a5d5d5be-99cc-4091-8d68-9db489700ed0